2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Prospective Study of Switching from Tacrolimus to Low-Dose Cyclosporine A Preserving Allograft Function in BK Virus-Associated Nephropathy
Background: Tacrolimus(Tac) -mycophenolic acid compared to cyclosporine is an independent risk factor for BK virus-associated nephropathy (BKVAN). Cyclosporine A (CsA) can inhibit BKV replication in…2018 American Transplant Congress
Identification of T Cells as Target of Intervention to Decrease Anti-LG3 Autoantibody Levels Prior to Transplantation
Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Autoantibodies against perlecan/LG3 fragment (anti-LG3) have been associated with accelerated allograft rejection and long-term renal allograft dysfunction. Intriguingly, anti-LG3 are present prior to transplantation in…2018 American Transplant Congress
Tacrolimus-Based Maintenance Immunosuppression Decreases the Number of Peripheral Blood Transitional B Cells in Nonhuman Primates
Center for Transplantation Sciences, Mass General Hospital, Boston, MA.
IntroductionElevated frequencies of transitional B cells have been reported in patients tolerant of renal allografts, as defined by stable graft function after withdrawal of immunosuppression…2018 American Transplant Congress
End Stage Renal Disease after Face Transplant
Purpose Renal failure as an outcome of chronic immunosuppression is a known complication of organ transplantation. We report the first case of end stage renal…2018 American Transplant Congress
High Calcineurin Inhibitor Intra Patient Variability is Associated with Early Renal Allograft Inflammation, Chronicity and Loss
High CNI IPV has been associated with poor kidney allograft outcomes, albeit in small limited studies. We evaluated effect of CNI IPV (the degree of…2018 American Transplant Congress
New Onset Diabetes after Kidney Transplant: Comparisons of Risks Associated with Various Steroid-Containing Calcineurin Inhibitor and Sirolimus Regimens
INTRODUCTION: We aimed to examine the risk of new onset diabetes after transplant (NODAT) associated with the following maintenance immunosuppression regimens in kidney transplant recipients…2018 American Transplant Congress
Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation
Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Outcomes in Liver Transplant Patients on Renal Sparing Protocol
As liver transplant outcomes have improved, long term native kidney function has taken a critical role in patient survival. Calcineurin inhibitors (CNIs), such as Tacrolimus…
American Transplant Congress abstracts